Related Experiment Video

Updated: Aug 29, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Doxorubicin for metastatic breast cancer: time for a change?

Franco Muggia

    Cancer Investigation
    |January 23, 2004
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Aug 29, 2026

    Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
    08:57

    Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

    Published on: October 5, 2017

    Related Concept Videos

    Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

    Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

    Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
    Phenothiazines, such as prochlorperazine...

    Articles linked to this work by shared authors, journal, and citation graph.

    PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.

    Cancer drug resistance (Alhambra, Calif.)·2022

    History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications.

    Cancer drug resistance (Alhambra, Calif.)·2022

    Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.

    Gynecologic oncology·2021

    Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma.

    Gynecologic oncology reports·2020

    Endometrial adenocarcinoma presenting as a suprasellar mass: lessons to be learned.

    Ecancermedicalscience·2020

    Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.

    Cancer chemotherapy and pharmacology·2020

    Mechanisms of Resistance to Immune Checkpoint Inhibitors and Therapeutic Strategies to Overcome Them: An Integrative Review.

    Cancer investigation·2026

    Predictive Value of the High-Sensitivity C-Reactive Protein/HDL-Cholesterol Ratio for Cardiovascular and Cancer-Specific Mortality in Cancer Survivors: A Study from NHANES 2015-2018.

    Cancer investigation·2026

    Precision Pancreatic Cancer Care: From Early Detection to Adaptive Precision Oncology.

    Cancer investigation·2026

    Measurement Properties of the Brazilian-Portuguese Version of Memorial Symptom Assessment Scale in Hospitalized Patients Undergoing Chemotherapy: A Longitudinal Study.

    Cancer investigation·2026

    Cancer Stem Cell-Targeted Therapies in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.

    Cancer investigation·2026

    Incidence, Management, and Clinical Outcomes of Cardiovascular Adverse Events in Patients Receiving ALK Inhibitors for Advanced Non-Small Cell Lung Cancer: A Real-World Single-Center Analysis.

    Cancer investigation·2026

    Aluminum-based salts: an unorthodox but simple way to treat molluscum contagiosum and cutaneous warts.

    F1000Research·2026

    Post-diagnosis cannabis use and its association with health status and quality of life in cancer survivors.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

    Aloesin mitigates cisplatin-induced nephrotoxicity by suppressing NF-κB-mediated oxidative stress and modulating Bax/Bcl-2/caspase pathways.

    Naunyn-Schmiedeberg's archives of pharmacology·2026

    [Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].

    Urologie (Heidelberg, Germany)·2026

    ITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell carcinoma by upregulating RAD51AP1 expression.

    Oncogene·2026

    Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

    British journal of haematology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us